Bicalutamide study for early bladder cancer in men
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man age 18 or older
- Your bladder cancer must be non-muscle invasive, confirmed by cystoscopy or imaging
- You must have had a CT or MRI scan of the belly and pelvis within the last 6 months showing no spread to the upper urinary tract or distant areas
- You must not have used certain hormone-related cancer medicines in the last 6 months
- You must be able to consent and do study visits and tests
- You must meet basic blood and urine test thresholds (blood counts, liver numbers) and have an appropriate urine culture result
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—durvalumab and monalizumab—for people with early-stage bladder cancer that hasn't spread into the muscle and has persisted or returned after BCG treatment. The goal is to see if this combination can control the cancer and delay or avoid the need for bladder removal surgery.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new Non-Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.